Boston Scientific began a deal to acquire Valencia Technologies, a company that develops and sells solution to treat bladder dysfunction. Valencia’s eCoin system is an implantable tibial nerve stimulation (ITNS) device to treat urinary urge incontinence (UUI), a common symptom of overactive bladder (OAB).

The eCoin system was approved by the U.S. Food and Drug Administration (FDA) in 2022. The coin-sized device is placed under the skin near the ankle in a minimally invasive procedure. The device is meant for people who have undergone a successful trial of percutaneous tibial nerve stimulation (PTNS) or those who are intolerant to or have inadequate response to more conservative UUI treatments.

Once it’s implanted, eCoin intermittently and automatically stimulates the tibial nerve to regulate how the brain communicates with the bladder. In eCoin’s pivotal clinical trial, 68% of patients responded with at least a 50% reduction in UUI episodes.

“The addition of the eCoin system to the Boston Scientific portfolio will enable us to expand into implantable tibial nerve stimulation (ITNS), a high-growth adjacency for our Urology business,” said Meghan Scanlon, senior vice president and president, Urology, Boston Scientific. “ITNS technology complements our existing pelvic health product line, and we look forward to offering a more comprehensive set of treatment options to patients across the care continuum.”

Boston Scientific anticipates to complete the acquisition of Valencia in the first half of 2026. The transaction’s financial terms were not disclosed.

In September, the company announced a deal to buy Elutia’s BioEnvelope business for $88 million. The bioenvelopes were designed to protect patients receiving implantable medical devices.